Breaking News Instant updates and real-time market news.

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:53
10/21/18
10/21
13:53
10/21/18
13:53

Loxo announces larotrectinib clinical update in patients with TRK fusion cancers

Loxo Oncology (LOXO) announced updated clinical data for larotrectinib, an investigational oral, selective, and CNS-active TRK inhibitor, in adult and pediatric patients with TRK fusion cancers. The update included approximately one year of additional follow-up for the 55 patients described in the larotrectinib New England Journal of Medicine publication from February 2018. In addition, the update included data for an additional 67 patients who were subsequently enrolled across the larotrectinib development program. As of a data cut-off date of July 30, 2018, median duration of response had not been reached in either dataset. Loxo Oncology and Bayer (BAYRY) are engaged in a collaboration for the development and commercialization of larotrectinib. The U.S. Food and Drug Administration has accepted the New Drug Application submitted by Loxo Oncology, and granted Priority Review for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring a neurotrophic tyrosine receptor kinase gene fusion. The FDA has set a target action date of November 26, 2018, under the Prescription Drug User Fee Act. Bayer has submitted a Marketing Authorization Application in the EU and additional filings in other markets are underway. Larotrectinib was well tolerated, with the majority of adverse events recorded as grade 1 or 2. No treatment-related grade 3 or 4 adverse events occurred in more than 5% of patients. Eleven patients required larotrectinib dose reductions. In all cases, patients whose doses were reduced maintained their best response at the lower dose. One patient discontinued larotrectinib due to an adverse event.

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

LOXO Loxo Oncology
$160.01

-7.58 (-4.52%)

10/08/18
10/08/18
UPGRADE
Target $190

Outperform
Loxo Oncology upgraded to Outperform on LOXO-292 update at IFS Securities
As previously reported, IFS Securities analyst David Bouchey upgraded Loxo Oncology to Outperform from Market Perform, with $190 price target, after the company reported updated results from its Phase I/II trial for LOXO-292. The analyst believes the response rates for LOXO-292 continue to look "very strong," the safety data is "excellent" and early results show that these responses appear durable. So far, the drug has outperformed expectations, he adds.
10/08/18
IFSG
10/08/18
UPGRADE
IFSG
Outperform
Loxo Oncology upgraded to Outperform from Market Perform at IFS Securities
10/07/18
PIPR
10/07/18
NO CHANGE
Target $200
PIPR
Overweight
Loxo Oncology's 292 remains on top after RET data updates, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren reiterates an Overweight rating and $200 price target for Loxo Oncology (LOXO) after the company provided an update of the thyroid patients in the Phase I/II study of LOXO-292. The analyst highlights that in the largest patient population the response rate increased from 45% to 59% with three additional patients responding between 9 and 12 months. Blueprint Medicines' (BPMC) competing BLU-667 reported a 49% ORR in a similar patient population and recall that adverse events of hypertension are still a concern, he notes. Van Buren believes that the 667's safety profile could continue to look worse as it continues to administer the drug to patients at higher doses and that treatment discontinuations could increase. Overall, the analyst believes Loxo's 292 appears to be the superior RET inhibitor in development, both in terms of efficacy and safety and could easily become a $1B+ drug.
09/26/18
STFL
09/26/18
NO CHANGE
Target $217
STFL
Buy
Loxo data not 'transformational,' but keeps inspiring confidence, says Stifel
Stifel analyst Stephen Willey said the incremental follow-up data from Loxo Oncology's (LOXO) LIBRETTO-001 trial isn't "transformational," but it does confirm his confidence in the establishment of a high competitive hurdle for LOXO-292, which he sees being a "best-in-class" and first-to-market asset in a $1B+ market. He remains confident LOXO-292 is the superior asset, but acknowledges the anticipation of Blueprint Medicines' (BPMC) updated BLU-667 data at some point in late-FY18 to early-FY19 could serve as a bit of headwind on Loxo shares nearer to that data release. Willey keeps a Buy rating and $217 price target on Loxo shares.
BAYRY Bayer
$0.00

(0.00%)

09/20/18
SBSH
09/20/18
UPGRADE
SBSH
Buy
Bayer upgraded to Buy from Neutral at Citi
Citi analyst Peter Verdult upgraded Bayer to Buy saying the current risk/reward is "difficult to ignore" with investor sentiment at "rock bottom." The analyst believes the negative earnings revisions have likely bottomed out.
09/18/18
09/18/18
UPGRADE

Bayer upgraded to Buy from Hold at M.M. Warburg
M.M. Warburg analyst Ulrich Huwald upgraded Bayer to Buy and raised his price target for the shares to EUR 88.50 from EUR 85.
09/11/18
EXAN
09/11/18
DOWNGRADE
EXAN
Neutral
Bayer downgraded to Neutral from Outperform at Exane BNP Paribas
08/27/18
08/27/18
UPGRADE
Target $34

Neutral
Portola Pharmaceuticals upgraded to Neutral as MARINER sinks at Credit Suisse
As previously reported, Credit Suisse analyst Vamil Divan upgraded Portola Pharmaceuticals (PTLA) to Neutral from Underperform after Johnson & Johnson (JNJ)/Bayer (BAYRY) presented disappointing data for Xarelto in the acute medically ill population at ESC. The analyst notes that the data avoids a worst case scenario for Portola's Bevyxxa by essentially removing a potentially strong competitor, but does put the pressure on Portola to successfully change medical practice on its own, without help from a larger player such as Johnson & Johnson. Divan also raised his price target on Portola's shares to $34 from $28.

TODAY'S FREE FLY STORIES

MSI

Motorola Solutions

$129.97

0.72 (0.56%)

18:48
11/16/18
11/16
18:48
11/16/18
18:48
Hot Stocks
Motorola Solutions: ITC confirms Hytera products infringe Motorola patents »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 18

    Dec

  • 19

    Dec

PCG

PG&E

$24.39

6.62 (37.25%)

18:23
11/16/18
11/16
18:23
11/16/18
18:23
Periodicals
CPUC isn't ruling out board shuffle, breakup for PG&E, Bloomberg says »

The California Public…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABX

Barrick Gold

$13.04

0.05 (0.38%)

18:00
11/16/18
11/16
18:00
11/16/18
18:00
Periodicals
Barrick Gold looking to add more copper, bullion assets, Reuters reports »

Barrick Gold is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTR

Aqua America

$33.05

0.165 (0.50%)

17:57
11/16/18
11/16
17:57
11/16/18
17:57
Hot Stocks
Aqua America CEO acquires over 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRE

Real Estate SPDR

$33.45

0.445 (1.35%)

, XLB

S&P Select Materials SPDR

$55.23

0.53 (0.97%)

17:39
11/16/18
11/16
17:39
11/16/18
17:39
General news
Week ending ETF scorecard: Real Estate leads, Consumer Discretionary slumps »

S&P500 SECTORS: Real…

XLRE

Real Estate SPDR

$33.45

0.445 (1.35%)

XLB

S&P Select Materials SPDR

$55.23

0.53 (0.97%)

XLU

Utilities SPDR

$54.86

0.77 (1.42%)

XLI

Industrial Select Sector SPDR

$72.00

(0.00%)

XLV

Health Care Select Sector SPDR

$92.05

0.91 (1.00%)

XLF

Financial Select Sector

$26.78

0.03 (0.11%)

XLP

Consumer Staples Sector SPDR

$56.04

0.15 (0.27%)

XLE

Energy Select Sector SPDR

$67.23

0.76 (1.14%)

XLC

Communication Services Select Sector SPDR Fund

$44.88

-0.2 (-0.44%)

XLK

Technology Select Sector SPDR

$68.22

-0.1 (-0.15%)

XLY

Consumer Discretionary Sector SPDR

$106.37

-0.43 (-0.40%)

GLD

SPDR Gold Shares

$115.56

0.82 (0.71%)

SLV

iShares Silver Trust

$13.55

0.115 (0.86%)

USO

United States Oil Fund

$12.07

0.08 (0.67%)

UNG

United States Natural Gas Fund

$35.43

3.63 (11.42%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$83.24

-0.27 (-0.32%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$111.73

0.23 (0.21%)

TLT

iShares 20+ Year Treasury Bond Fund

$114.65

0.61 (0.53%)

IEF

iShares 7-10 Year Treasury Bond ETF

$101.13

0.3 (0.30%)

SHY

iShares 1-3 Year Treasury Bond

$83.13

0.08 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQST

Aquestive Therapeutics

$17.02

0.23 (1.37%)

17:36
11/16/18
11/16
17:36
11/16/18
17:36
Hot Stocks
Aquestive receives CRL from FDA for tadalafil oral film »

Aquestive Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

DAKT

Daktronics

$7.67

0.07 (0.92%)

17:35
11/16/18
11/16
17:35
11/16/18
17:35
Hot Stocks
Daktronics adopts new shareholder rights agreement »

Daktronics announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

TI

Telecom Italia

$6.02

0.12 (2.03%)

17:33
11/16/18
11/16
17:33
11/16/18
17:33
Periodicals
Gubitosi viewed as frontrunner for Telecom Italia CEO job, Reuters says »

Veteran Italian manager…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAXR

Maxar Technologies

$18.77

-0.59 (-3.05%)

17:30
11/16/18
11/16
17:30
11/16/18
17:30
Hot Stocks
Maxar Technologies shareholders approve U.S. domestication »

Maxar Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLUG

Plug Power

$1.83

(0.00%)

17:28
11/16/18
11/16
17:28
11/16/18
17:28
Syndicate
Breaking Syndicate news story on Plug Power »

Plug Power files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSB

GlobalSCAPE

$4.55

-0.02 (-0.44%)

17:22
11/16/18
11/16
17:22
11/16/18
17:22
Syndicate
Breaking Syndicate news story on GlobalSCAPE »

GlobalSCAPE files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQIX

Equinix

$388.18

2.67 (0.69%)

17:19
11/16/18
11/16
17:19
11/16/18
17:19
Hot Stocks
Equinix's Lee sells 2,792 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 10

    Dec

LMT

Lockheed Martin

$301.06

-4.42 (-1.45%)

17:17
11/16/18
11/16
17:17
11/16/18
17:17
Hot Stocks
Lockheed Martin awarded $282.09M Naval Sea Systems Command contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLGT

Teligent

$2.56

0.045 (1.79%)

17:16
11/16/18
11/16
17:16
11/16/18
17:16
Hot Stocks
Teligent receives notification of deficiency from Nasdaq »

Teligent said that on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STAF

Staffing 360 Solutions

$1.82

0.07 (4.00%)

17:16
11/16/18
11/16
17:16
11/16/18
17:16
Syndicate
Breaking Syndicate news story on Staffing 360 Solutions »

Staffing 360 Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

IMMR

Immersion

$9.56

-0.14 (-1.44%)

17:12
11/16/18
11/16
17:12
11/16/18
17:12
Hot Stocks
Breaking Hot Stocks news story on Immersion »

Man Group reports 4.84%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATNX

Athenex

$11.95

0.74 (6.60%)

17:10
11/16/18
11/16
17:10
11/16/18
17:10
Hot Stocks
Breaking Hot Stocks news story on Athenex »

Perceptive Advisors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 02

    Dec

TSRO

Tesaro

$34.96

8.39 (31.58%)

17:08
11/16/18
11/16
17:08
11/16/18
17:08
Recommendations
Tesaro analyst commentary at Piper Jaffray »

Piper Jaffray says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

EEI

Ecology & Environment

$10.50

-2 (-16.00%)

17:05
11/16/18
11/16
17:05
11/16/18
17:05
Hot Stocks
Ecology & Environment receives noncompliance notice from Nasdaq »

Ecology and Environment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEE

Ameren

$69.29

0.01 (0.01%)

16:58
11/16/18
11/16
16:58
11/16/18
16:58
Hot Stocks
Ameren exec Nelson sells $690,000 worth of common shares »

Ameren SVP, general…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQS

Equus II Inc

$1.86

(0.00%)

16:56
11/16/18
11/16
16:56
11/16/18
16:56
Hot Stocks
Equus II Inc reports net assets of $46.6M as of September 30 »

Equus Total Return…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VAPO

Vapotherm

$17.10

-0.42 (-2.40%)

16:56
11/16/18
11/16
16:56
11/16/18
16:56
Hot Stocks
Breaking Hot Stocks news story on Vapotherm »

Redmile Group reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

COTY

Coty

$9.09

0.39 (4.48%)

16:55
11/16/18
11/16
16:55
11/16/18
16:55
Hot Stocks
Coty CEO acquires 2.3M common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

NVS

Novartis

$87.74

0.52 (0.60%)

16:54
11/16/18
11/16
16:54
11/16/18
16:54
Upgrade
Novartis rating change at Goldman Sachs »

Novartis upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 03

    Dec

VIAB

Viacom

$33.00

1.13 (3.55%)

16:52
11/16/18
11/16
16:52
11/16/18
16:52
Syndicate
Breaking Syndicate news story on Viacom »

Viacom files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

  • 04

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.